Regulations and Regulatory Issues

The majority of comments on the scheduling of cannabis favored change, though several other aspects of cannabis policy remain to be addressed.

The 23rd episode in the monthly webinar series discusses vape manufacturing, consumers, and solutions to health and safety risks.

The Colorado Department of Public Health and Environment (CDPHE) now regulates certain hemp manufacturers. Here’s how to prepare for compliance inspections, which may become a trend to more states beyond Colorado.

The discussion surrounding intoxicating the manufacture and sale of hemp-derived cannabinoids continues with more proposals and challenges.

In reversal of recent developments, officials in Thailand have signaled that cannabis will not be re-criminalized.

Check out some of our most popular content from the first six months of the year 2024!

The first part of this column examines the fractured nature of state-based regulations and compares it with the federal limits for pharmaceutical products and dietary supplements.

Cannabis companies can face recalls due to issues like unhealthy levels of molds, yeasts, pesticides, and heavy metals, making it crucial to minimize recall chances and follow proper protocols to prevent fines or lawsuits.

The proposed rescheduling of cannabis holds profound implications for the industry, affecting everything from research and taxation to banking and market dynamics.

A recently added amendment to the 2024 Farm Bill would significantly impact intoxicating hemp-derived products.

The nonprofit, which is focused on advancing the cannabis industry, joins a network of industry experts from over a hundred different organizations.

The final installment of this webinar series discussed recommendations for new policies integrating cannabis into harm reduction efforts.

At the Cannabis Science Conference Spring 2024, toxicologist Cristelle Santos provided a deep dive into the need for better cannabis product safety standards.

This hour-long webinar covered consumer safety, interstate commerce, and the need for global standards, highlighting collaboration and evidence-based approaches for future regulatory frameworks.

Focusing on the potential effects for medical cannabis patients, Americans for Safe Access held a high-level presentation and discussion on the rescheduling of cannabis.

The US Attorney General has initiated the process to reclassify cannabis from a Schedule I to a less-restrictive Schedule III substance.

In this quick, onsite interview, Program Chair of the Compliance Track, Kim Stuck, shares the biggest buzz from the Cannabis Science Conference Spring 2024.

During Day 1’s General Session Kim Stuck, The Canna Consortium, moderated a panel featuring David Vaillencourt of S3 Collective, Ken Sobel Esq., and Susan Audino of S.A. Audino & Associates, LLC, where they shared their perspectives on cannabis’s recent federal rescheduling to Schedule III.

There have been a few changes when it comes to Organic Certification that you might not know about, so I’ll be dedicating this month’s blog to a certification opportunity for the hemp industry.

Multiple sources have reported that the US Drug Enforcement Administration will move to reclassify marijuana from Schedule I to Schedule III, effectively recognizing medical uses of cannabis and its reduced potential for abuse compared with other drugs.

In recognizing the 4/20 holiday, here is a selection of regulatory updates and commentary in the cannabis industry this year so far.

The cannabis business license application system has raised concerns with several stakeholders.

A collection of our most recent webinar coverage discussing medical research and testing methods.

Several efforts have been made to limit the prevalence of intoxicating hemp products.

In a big new move for Colorado, towards the end of 2023, the state approved a new set of hemp regulations that includes tighter restrictions over hemp derived cannabinoids, which were met with both pushback and acceptance from the industry.

This month’s webinar covered the many facets of fit for purpose testing of cannabis products.

At this moment I am in Barcelona, Spain for one of the biggest cannabis conventions in the world: Spannabis (1). I feel I would be remiss if I didn’t write my blog this month without touching on international legalization of cannabis and how that would affect the United States market.

To coordinate efforts for the rescheduling road ahead, the S3 Collective held a webinar for anyone with a stake in federal cannabis regulations.

On January 31, 2024, the GMP Collective presented the seventeenth episode in their ongoing webinar series, When Things Go Wrong.

The landscape of the cannabis industry is dynamic and continually evolving, so who is to say exactly how they will be enforcing or regulating cannabis if it does get rescheduled, but we can learn from what we have seen in the past and what we are hearing in the back rooms of regulatory agencies. This could be a significant shift that could reshape the industry. This change would signify a recognition of its medicinal value, open doors for new opportunities, and also have some consequences for companies not prepared for the shift. In this blog, we explore the potential implications of cannabis becoming a Schedule III substance and why obtaining current Good Manufacturing Practices (cGMP) 211 Certification from an accredited certifying body is crucial for ensuring the longevity and success of cannabis businesses. What we don’t know at this time is what kind of runway we have in implementing these new standards to be compliant with them. They could give 30 days or one year, but we just won’t know until it happens. The best thing you can do for your business now is become compliant with these standards before you are required to be so.